1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. GRANULES INDIA LTD.
Granules India Ltd.
NSE: GRANULES | BSE: 532482

Granules Live Share Price Today, Share Analysis and Chart

Mid-range Performer
BasketIn 1 Starfolio Basket
aboutGranules India Ltd. is a vertically integrated pharmaceutical company that spans the entire value chain from Active Pharmaceutical Ingredients (APIs) and Pharmaceutical Formulation Intermediates (PFIs) to Finished Dosages (FD). Established in 1991 an... Read More
US FDA Inspections
Ask AI about Granules
839.752.40(0.29%)

58.49% Gain from 52W Low

821.9K
NSE+BSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Board Meeting
The next board meeting for Granules is on 02 Nov 2026 for the purpose of Quarterly Results See details
Loading...
- / 100
- / 100
56.7 / 100
Mid-range PerformerThese stocks have strong quality. Their reasonable financials and technicals make them potentially attractive to investorsView SimilarEmbed DVM
Analyst Price Target
-

22

S

4

W

7

O

0

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

16Positive7Negative

Pass in checklist69.6%

045
55
100

PE Valuation Check

Right Now
Overvalued
-20.9%
1 Year Forward
Overvalued
-7.8%
INSIGHTGranules is overvalued at both current PE and future earnings estimates.

Granules Stock Price Analysis

Day Price Range

0.3% 1 Day return
839.8 (LTP)
837859.7
LowHigh

Week Price Range

5.7% 1 Week return
839.8 (LTP)
792.2859.7
LowHigh

Month Price Range

-0.8% 1 Month return
839.8 (LTP)
782859.7
LowHigh

52 Week Price Range

48.5% 1 Year return
839.8 (LTP)
529.8923.6
LowHigh
View full Price History/Seasonality

Granules Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Miss

Granules's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

CURRENT EPS
24.5
AVG. ESTIMATE
31.2
LOW ESTIMATE
29.9
HIGH ESTIMATE
32.3
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 27.4% in FY27

Consensus Recommendation

8 ANALYST Recommendations
BUY

The consensus recommendation from 8 analysts for Granules is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Granules Technical Analysis

Granules EMA & SMA

Bullish+8
8 bullish, 0 bearish
Bullish8
Bearish0
5 Day832.9
10 Day827.2
12 Day826.6
20 Day828.1
26 Day830.3
50 Day834.3
100 Day815.6
200 Day756.8

Granules Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202645.3%
Week50.9%
Month49.5%

Granules Active Candlesticks

Highwave Uptrend Long Legged Doji Uptrend Spinning Top Uptrend Gravestone Doji
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Granules Resistance and Support

845.48
Pivot
First Resistance854.0
Second Resistance868.2
Third Resistance876.7
First Support831.3
Second Support822.8
Third Support808.6
Day RSI53
Day MACD-3.7
Day MFI53.6
Day MACD Signal Line-8.2

Granules Beta

1 Month1.2
1 Year0.9
3 Month1.0
3 Year1

Granules Price Change Analysis

↓-0.8%
Over 1 Month
LowHigh
782.1859.7
↑1.8%
Over 3 Months
LowHigh
782.1923.7
↑20.0%
Over 6 Months
LowHigh
690.1923.7
↑48.5%
Over 1 Year
LowHigh
529.9923.7
All Technicals →

Granules Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Krishna Prasad ChigurupatiPromoter59,608,11121.9 %
Smallcap World Fund, IncFii12,386,9794.5 %
Basava Sankar Rao KolliPublic2,907,3301.1 %
Sbi Life Insurance Co. LtdDii7,929,9622.9 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Granules Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
KRISHNA PRASAD CHIGURUPATIBlockSell11 Sep 2026872.5013,295,129NSE
SBI LIFE INSURANCE COMPANY LIMITEDBlockPurchase11 Sep 2026872.50573,065NSE
OPTIMIX WHOLESALE GLOBAL EMERGING MARKETS SHARE TRUSTBlockPurchase11 Sep 2026872.50182,350NSE
GOLDMAN SACHS BANK EUROPE SEBlockPurchase11 Sep 2026872.501,173,916NSE
FLORIDA RETIREMENT SYSTEMBlockPurchase11 Sep 2026872.50416,692NSE
EMERGING MARKETS GROWTH FUND INCBlockPurchase11 Sep 2026872.5072,360NSE
EMERGING MARKETS EQUITY FUNDBlockPurchase11 Sep 2026872.50312,796NSE
EDELWEISS MUTUAL FUNDBlockPurchase11 Sep 2026872.50458,452NSE
CLARUS CAPITAL 1BlockPurchase11 Sep 2026872.50859,600NSE
CAPITAL INTERNATIONAL EMERGING MARKETS FUNDBlockPurchase11 Sep 2026872.5034,085NSE
All deals
All insider trades

Granules Corporate Actions

Granules Dividend history and yield

Granules dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Granules dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
130 Jul 2026
1.75FINAL30 Jul 2026Equity Share
231 Jul 2025
1.5FINAL31 Jul 2025Equity Share
330 Jul 2024
1.5FINAL-Equity Share
403 Aug 2023
1.5FINAL03 Aug 2023Equity Share
519 Jul 2022
0.75FINAL-Equity Share

Granules Board Meetings

Granules past and upcoming board meetings.

#Ex-Date
PurposeNotes
102 Nov 2026
Quarterly Results-
221 Jul 2026
Quarterly Results-
329 Apr 2026
Audited Results & Final Dividend-
423 Jan 2026
Quarterly Results-
513 Nov 2025
Quarterly Results-

Granules Stock Split

Granules stock split details, including announcement, record, and ex-split dates, along with the split ratios

#Ex-Date
Old FVNew FVRecord Date
123 Mar 2015
101-
All Corporate Actions

Granules Research Reports

Granules research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
122 Jul 2026Deven Choksey
Target
959853.8Accumulate12.32%-1.65%pdf
221 Jul 2026Emkay
Target
950853.8Buy11.27%-1.65%pdf
321 Jul 2026ICICI Direct
Target
1045853.8Buy22.39%-1.65%pdf
420 Jul 2026Motilal Oswal
Target
1010875.7Buy15.34%-4.11%pdf
508 Jul 2026Deven Choksey
Target
931859.55Hold8.31%-2.3%pdf
All Reports of Granules

Granules Corporate Filings

Granules BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
30 Oct 2026
Granules India Ltd-$ - 532482 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release
PDF
26 Oct 2026
Granules India Ltd-$ - 532482 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of the Earnings Conference call for Q2 and Half year of FY27.
PDF
24 Oct 2026
Granules India Ltd-$ - 532482 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mrs Chigurupati Uma Devi, Mrs Priyanka Chigurupati, Mrs Pragnya Chigurupati, Mr Harsha Chigurupati & PACs
PDF
24 Oct 2026
Granules India Ltd-$ - 532482 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mrs Chigurupati Uma Devi, Mrs Priyanka Chigurupati, Mrs Pragnya Chigurupati, Mr Harsha Chigurupati & PACs
PDF
24 Oct 2026
Granules India Ltd-$ - 532482 - Revised Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr. Krishna Prasad Chigurupati & PACs
PDF
VIEW ALL

Granules DocumentsAsk MarketMind AI

Granules Earnings Call

Granules earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
29 Sep 2026Granules India Ltd-$ - 532482 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationLink
27 Jul 2026Granules India Ltd-$ - 532482 - Transcript Of The Earnings Call For Q1 Of FY27Link
22 Jul 2026Granules India Ltd-$ - 532482 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
05 May 2026Granules India Ltd-$ - 532482 - Transcript Of The Earnings Conference Call For Q4 And Financial Year Ended On March 31, 2026.Link
29 Apr 2026Granules India Results Earnings Call for Q4FY26 & Full YearAudioVideo
view all

Granules Annual Reports

Granules financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link
2022Annual Report Mar-2022Link

Granules Credit Ratings

Granules credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
18 Jan 2026icra ratingsGranules India LimitedLong term rating upgraded to [ICRA]AA (Stable) and short term rating reaffirmedLink
15 Jan 2026india ratingsIndia Ratings Affirms Granules India’s Bank Loan Facilities at ‘IND AA-’/PositiveLink
05 Nov 2024icra ratingsGranules India LimitedRatings reaffirmedLink
17 Oct 2024india ratingsIndia Ratings Assigns Granules India’s Additional Bank Facilities at ‘IND AA-’/Positive; Affirms Existing Ratings Link
21 Sep 2023india ratingsIndia Ratings Discontinues Voluntary Issuer Rating Disclosure due to Regulatory Requirements; All Outstanding Instrument Rating Remain Unaffected for Granules India LimitedLink

Granules Investor Presentations

Granules investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
21 Jul 2026Granules India Ltd-$ - 532482 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
29 Apr 2026Granules India Ltd-$ - 532482 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
29 Apr 2026Granules India Ltd-$ - 532482 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationLink
23 Jan 2026Granules India Ltd-$ - 532482 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
13 Nov 2025Granules India Ltd-$ - 532482 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Granules - Company Profile

Granules Management Structure

Granules management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
PRIYANKA CHIGURUPATINon Independent Executive Director,Head(Marketing),Promoter283.6Mar 26
Chaitanya TummalaCompany Secretary,Compliance Officer-Mar 26
Mr. Mukesh SuranaChief Financial Officer-Mar 26
Dr. P.V. SrinivasChief Technology Officer,Head(R&D)-Mar 26
Mr. Sanjay KumarPresident,Chief Strategy Officer-Mar 26
Mr. Rajesh KapoorPresident,Global Head(Quality)-Mar 26
Mr. Manikandan RamalingamSenior Vice President,Head(Formulations,R & D)-Mar 26
Mr. Ramraj RangarajaluPresident,Head(Formulations,Operations)-Mar 26
Dr. Baskaran PnPresident,Head(API Business)-Mar 26
Dr. Vijay RaghavanPresident(Global Portfolio Management)-Mar 26
Mr. Vinodkumar ParurChief Human Resources Officer-Mar 26

Granules Board of Directors

Granules Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
C Krishna PrasadCMD & Executive Director2836Mar 26
Uma Devi ChigurupatiED (Non-Independent)283.6Mar 26
Harsha ChigurupatiED (Non-Independent)283.6Mar 26
Priyanka ChigurupatiExecutive Director283.6Mar 26
Arun SawhneyIndependent Non Exe. Director44.36Mar 26
Saumen ChakrabortyIndependent Non Exe. Director42.11Mar 26
Kapil MehanIndependent Non Exe. Director42.11Mar 26
S RaviIndependent Non Exe. Director40.61Mar 26
K B Sankara RaoNon-Exec & Non-Independent Dir39.11Mar 26
Rajiv KakodkarIndependent Non Exe. Director38.36Mar 26
Sucharita Rao PalepuIndependent Non Exe. Director35.11Mar 26
Chaitanya TummalaCompany Sec. & Compli. Officer-Mar 26
Website: www.granulesindia.com

About the company - Business Profile

Granules India Ltd. is a vertically integrated pharmaceutical company that spans the entire value chain from Active Pharmaceutical Ingredients (APIs) and Pharmaceutical Formulation Intermediates (PFIs) to Finished Dosages (FD). Established in 1991 and headquartered in Hyderabad, India, the company serves over 300 customers across more than 80 countries. It holds a significant market position in large-volume "core" molecules such as Paracetamol, Metformin, Ibuprofen, Guaifenesin, and Methocarbamol, leveraging its high-capacity manufacturing to achieve cost leadership.

Key Points

  • Key Facts: Founded in 1991; Headquartered in Hyderabad, India; Publicly listed on BSE (532482) and NSE (GRANULES).
  • Operations and Resources: The company operates 8 manufacturing facilities (7 in India, 1 in the USA) and 4 R&D centers. Notable assets include the Gagillapur facility, one of the world's largest single-site FD plants, and a dedicated PFI facility in Bonthapally.
  • Business Model: Granules utilizes a vertically integrated model to drive efficiencies and ensure supply chain security. It excels in high-volume, high-efficiency manufacturing of essential medicines while expanding into "Complex Generics" (including oncology and ADHD treatments) and CDMO services through its peptide division.
  • Revenue Breakdown (FY2024-25):
    • By Segment: Finished Dosages (FD) contributed the majority of revenue (~74% in recent quarters), followed by PFI and API.
    • By Geography: Exports contribute over 90% of total revenue, with North America being the primary market.
  • Key Products and Innovation:
    • Core Portfolio: Leading manufacturer of Paracetamol, Ibuprofen, and Metformin.
    • Complex Generics: Portfolio expansion includes ADHD medications (Adderall IR & XR) and Multi-Unit Pellet System (MUPS) products.
    • Technology: Strategic focus on "Green" chemistry and biocatalysis. The company acquired Senn Chemicals AG, Switzerland, to bolster its Peptides and CDMO capabilities.
  • Employee Count: Total workforce of approximately 6,166 as of March 31, 2025, with a 13% female representation.
  • Subsidiaries: Major units include Granules Pharmaceuticals Inc. (USA) for formulation R&D and Granules Life Sciences (GLS) for specialized manufacturing.
  • Strategic Initiatives: Current focus is on "Project CZRO," aimed at achieving Net-Zero targets by 2050 through complete supply chain decarbonization. The company is also expanding into high-growth areas like oncology and peptide manufacturing to shift toward margin-accretive products.

Financial Summary (Consolidated FY 2024-25)

  • Revenue: ₹44,816 million (approx. 1% decline YoY).
  • EBITDA: ₹9,452 million (10% growth YoY; Margin: 21.1%).
  • PAT: ₹5,015 million (24% growth YoY).
  • Gross Margin: ₹27,559 million (Margin: 61.5%).
  • ROCE: 16.6%.
  • Net Debt/EBITDA: 0.75x.

References

  1. Annual Report May 2025
  2. Investor Presentation Jan 2026
  3. Investor Presentation Nov 2025
  4. Annual Report May 2024

Granules FAQ

Granules today is trading in the green, up by 0.29% at ₹839.75.
Granules is currently trading up 0.29% on an intraday basis. In the past week the stock rose 5.66%. Stock has been up 1.83% in the past quarter and rose 48.47% in the past year. You can view this in the share price history/seasonality section.
Granules is listed on NSE with the ticker GRANULES and on BSE as 532482. It's currently trading on NSE at a share price of ₹839.75 and on BSE with a share price of ₹841.1.
The market cap of Granules is ₹20,808.74 Cr. as of Oct 30, 2026.
Granules announced a FINAL dividend of 175% which equals ₹1.75 in Jul 30, 2026.The last three ex-dates for Granules were Jul 31, 2025, Jul 30, 2024 and Aug 03, 2023. To view the full dividend history of Granules click here.
Granules has never issued bonus shares, but it has issued 1 stock split since its BSE/NSE listing. The latest announcement for Granules stock split was on Mar 23, 2015 at a ratio of 10:1.
Granules reported ₹1,479.04 Cr. in revenue, ₹179.96 Cr. in net profit, and ₹341.18 Cr. in EBITD as of Jul 21, 2026 for Q1 FY26-27.
According to the predictions of 8 analysts, the share price prediction for Granules is ₹907.25 with an upside of 8%.
The PE ratio of Granules is 31.42 as of Oct 30, 2026.
The PB ratio of Granules is 3.95 as of Oct 30, 2026.
You can view the latest analyst reports on the Granules reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×